In research involving human participants as trial subjects or tissue
An interpretation of results with Syncardia Total Artificial
1. Presented by: Mrs. Smart-Patterson
Wiley College Spring 2016
Bio Seminar II
2. ASAIO Journal:
American Society of Artificial Internal Organs
November/December 2014 - Volume 60 - Issue 6 - p 626–634
doi: 10.1097/MAT.0000000000000132
Adult Circulatory Support
Published
3. GianlucaTorregrossa, Michiel Morshuis,Robin
Varghese, Leila Hosseinian,VladimiroVida,
VincenzoTarzia,Antonio Loforte,Daniel
Duveau,Francisco Arabia, Pascal
Leprince,Vigneshwa Kasirajan,
Friedhelm Beyersdorf, Francesco Musumeci,
Roland Hetzer,Thoamas Krabatsch,
Jan Gummert,
Jack Copeland and Gino Gerosa
Authors
4. Origin Data Collected Age Support
Period
Primary
Diagnosis
Dec. 2011 Survival Rate
Infections
Thromboembolic
Hemorrhagic
Device Failure
Anti-thrombic
Therapy
50
+ - 1.57years
554 days Dilated
cardiomyopathy
(23)
Ischemic (15)
Other (9)
Introduction
5. criteria
• SyncardiaTAH device
• For at least 1 year
criteria
• Obtained between 1989-2011
• Data complete and FullyAvailable
criteria
• At least had 1 of the INTERMATICS class (1-3)
• BSA of at least 1.7
• Anterior/posterior mediastinum of 10cm
Method
6. 1 year post SyncardiaTAH
successful
Died
currently supported
device failure
Results
7.
8. Reliable and effective in replacing the entire heart
Patients supported for at least 1 year with SyncardiaTAH:
-TAH device leading cause of death (2 cases)
-Primary cause of death: Infections and Hemorrhagic.
Conclusion
